Navigation Links
Common Heart Drug Might Improve Lung Cancer Survival
Date:1/9/2013

By Steven Reinberg
HealthDay Reporter

WEDNESDAY, Jan. 9 (HealthDay News) -- New research suggests that beta blockers, medications that are used to control blood pressure and heart rhythms, may also help lung cancer patients live longer.

The researchers found that patients with non-small-cell lung cancer being treated with radiation lived 22 percent longer if they were also taking these drugs.

"These findings were the first, to our knowledge, demonstrating a survival benefit associated with the use of beta blockers and radiation therapy for lung cancer," said lead researcher Dr. Daniel Gomez, an assistant professor in the department of radiation oncology at the University of Texas M.D. Anderson Cancer Center in Houston.

"The results imply that there may be another mechanism, largely unexplored, that could potentially reduce the rates of tumor spread in patients with this very aggressive disease," he added.

The report was published Jan. 9 in the Annals of Oncology.

For the study, Gomez's team compared the outcomes of more than 700 patients undergoing radiation therapy for lung cancer.

The investigators found that the 155 patients taking beta blockers for heart problems lived an average of almost two years, compared with an average of 18.6 months for patients not taking these drugs.

The findings held even after adjusting for other factors such as age, stage of the disease, whether or not chemotherapy was given at the same time, presence of chronic obstructive pulmonary disease and aspirin use, the researchers noted.

Beta blockers also improved survival without the disease spreading to other parts of the body and survival without the disease recurring, they added.

Beta blockers, however, made no difference in the length of survival without the disease progressing in the part of the lungs where it started, the study authors pointed out.

How beta blockers might slow cancer's spread isn't known. However, the researchers speculate that these drugs may work by suppressing a hormone called norepinephrine, which is known to promote the spread of cancer cells.

"Right now, we would not advocate that patients take beta blockers for this purpose, until these findings can be validated by prospective trials," Gomez said. "In addition, future studies will help us to understand if the mechanism that we propose is correct, and thus if beta blockers are indeed directly affecting the aggressiveness of this cancer or if these findings are due to the activation or inhibition of another pathway."

For one expert, the study raises more questions than it answers.

"It is unclear whether beta blockers need to be started before the cancer is found, or if they still have a utility once the diagnosis is made," said Dr. Len Horovitz, a pulmonologist at Lenox Hill Hospital in New York City.

In addition, Horovitz wonders whether other drugs that block hormones might serve the same purpose.

One thing is clear, however, he added. People should not start taking beta blockers in hopes of preventing or controlling lung cancer, he said.

Horovitz did say he thinks trials testing whether or not beta blockers or other hormone-blocking drugs prevent the spread of lung cancer should be done.

Although the study found a link between beta blocker use in patients undergoing radiation therapy and increased non-small-cell lung cancer survival, it did not prove cause-and-effect.

More information

For more on lung cancer, visit the U.S. National Cancer Institute.

SOURCES: Daniel Gomez, M.D., assistant professor, department of radiation oncology, University of Texas M.D. Anderson Cancer Center, Houston; Len Horovitz, M.D., pulmonologist, Lenox Hill Hospital, New York City; Jan. 9, 2013, Annals of Oncology


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Researchers reveal most effective treatment for common kidney disorder
2. Binge Drinking Common Among U.S. Women, Girls: CDC
3. Researchers identify new target for common heart condition
4. Common Blood Pressure Drugs Might Lower Dementia Risk
5. Psychological common ground could ease tensions among those with different religious beliefs
6. What do cyborgs, shale gas and TSCA reform have in common?
7. Common data determinants of recurrent cancer are broken, mislead researchers
8. Dr. Alavi Responds to Common Plastic Surgery Myths
9. Car Crashes Common for Sleepy Doctors in Training: Study
10. Probiotic Action Responds to Article Answering Common Questions About Acne
11. Some Kids Abusing Common Baking Ingredients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Common Heart Drug Might Improve Lung Cancer Survival
(Date:2/8/2016)... PISCATAWAY, N.J. (PRWEB) , ... February 08, 2016 ... ... of protective footwear and clothing, announced expansion into Canada to provide its range ... has opened a sales office in Quebec City that will provide bilingual customer ...
(Date:2/8/2016)... GA (PRWEB) , ... February ... ... technology and security executive networking and relationship-marketing firm, announced today that nominations ... 2016 Information Security Executive® (ISE®) West Awards. , Awards include the ...
(Date:2/8/2016)... ... 2016 , ... GrassrootsHealth published data from its D*action public ... in the GrassrootsHealth cohort with substantially higher vitamin D levels than a cohort ... states Carole Baggerly, Director of GrassrootsHealth, “the safety and benefits of vitamin ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... The ... annually in this country. The AutismOne 2016 Conference, which is being held May 25-29 ... often won’t hear elsewhere about helpful interventions and causes of chronic illness in children. ...
(Date:2/7/2016)... ... February 07, 2016 , ... Dr. Todd ... to his medical and surgical expertise. Technically known as deoxycholic acid or previously ... as a non-surgical alternative for reduction of fat below the chin (aka the ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... -- http://www.researchandmarkets.com/research/x6mkjm/knee ) has announced the ... by Product Type (Primary (Cemented & Cementless), Partial, ... Japan, Bric, Turkey, Indonesia - Global Analysis and ... --> http://www.researchandmarkets.com/research/x6mkjm/knee ) has announced ... Market by Product Type (Primary (Cemented & Cementless), ...
(Date:2/8/2016)...  Avista Pharma Solutions ("Avista Pharma") announced today that ... Officer (CFO). Mr. Setzer is a finance and operations ... roles within growing technology and life science companies. Prior ... Director of Finance at INC Research, a publicly traded ... . Previously, Mr. Setzer served as CFO of Expression ...
(Date:2/8/2016)... Therapeutics, Inc. announced today that the United States Patent and ... the use of NephroFlow to treat acute kidney injury (AKI). ... "We are pleased to secure our rights to such a ... HemaFlo,s founder, said, "We are pleased to secure our rights ... Dale Peterson , PhD, HemaFlo,s founder, said, "We are pleased ...
Breaking Medicine Technology: